Company Formed by Alamar Biosciences and Frazier Life Sciences Attobody™ Platform Generates Small Format Binders for Hard-to-drug Targets FREMONT and MENLO PARK– June 20, 2023 – Alamar Biosciences, a company
Alamar Biosciences Unveils Novel Proteomics Platform with Best-in-Class Sensitivity and High Multiplexing Capability Multiplex analysis of 204 serum proteins with attomolar sensitivity and 10 logs dynamic range enables accurate measurement
• Mologic leverages Alamar’s ultra-high affinity antibodies for SARS-CoV-2 diagnostics • Partnership will facilitate rapid responses to future pandemics Bedfordshire, UK and Fremont, CA, US – 4 May 2022 –
Fremont, CA and Rockville, MD – 15 February 2022 – Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer
Alamar selects Abcam as a key provider of antibody content for its proprietary NULISA technology platform Fremont, CA, US and Cambridge, UK – 04 January 2022 – Alamar Biosciences (Alamar),
Looking for more information? Contact us today and a representative will reach out to you soon.
Alamar Biosciences, Inc.
47071 Bayside Pkwy
Fremont, CA 94538
1 (510) 626-9888
Fax: (510) 605-5062
